The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The prognostic significance of achieving mCR with hypomethylating agent-based therapy in MDS
Maximilian Stahl, MD, Yale Cancer Center, New Haven, CT, discusses the prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome (MDS). He highlights the updated 2023 working group criteria for assessing response to therapy, noting the removal of the mCR response category. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
